The estimated Net Worth of Diane E. Wilfong is at least $3.62 Milione dollars as of 6 February 2023. Ms Wilfong owns over 1,864 units of Gilead Sciences stock worth over $2,636,621 and over the last 13 years she sold GILD stock worth over $982,224.
Ms has made over 21 trades of the Gilead Sciences stock since 2012, according to the Form 4 filled with the SEC. Most recently she exercised 1,864 units of GILD stock worth $150,872 on 6 February 2023.
The largest trade she's ever made was exercising 16,255 units of Gilead Sciences stock on 1 November 2022 worth over $1,181,739. On average, Ms trades about 2,721 units every 143 days since 2012. As of 6 February 2023 she still owns at least 32,575 units of Gilead Sciences stock.
You can see the complete history of Ms Wilfong stock trades at the bottom of the page.
Diane E. Wilfong is the Sr. VP, Corp. Controller & Chief Accounting Officer at Gilead Sciences.
Ms Wilfong is 59, she's been the Sr. VP e Corp. Controller & Chief Accounting Officer of Gilead Sciences since . There are 8 older and 16 younger executives at Gilead Sciences. The oldest executive at Gilead Sciences, Inc. is Richard Whitley, 74, who is the Independent Director.
Diane's mailing address filed with the SEC is GILEAD SCIENCES, INC., 333 LAKESIDE DRIVE, FOSTER CITY, CA, 94404.
Over the last 21 years, insiders at Gilead Sciences have traded over $221,090,692 worth of Gilead Sciences stock and bought 30,121 units worth $1,879,767 . The most active insiders traders include John C Martin, Norbert W Bischofberger e John F Milligan. On average, Gilead Sciences executives and independent directors trade stock every 9 days with the average trade being worth of $3,341,365. The most recent stock trade was executed by Deborah H Telman on 10 September 2024, trading 639 units of GILD stock currently worth $51,721.
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.
Gilead Sciences executives and other stock owners filed with the SEC include: